Drug
AN0025
AN0025 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Active, not recruiting1
Completed1
Suspended1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
active_not_recruiting125%
completed125%
suspended125%
withdrawn125%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_1
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
NCT04975958
withdrawnphase_1
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
NCT05358691
suspendedphase_1
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
NCT05191667
active_not_recruitingphase_1
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
NCT04432857
Clinical Trials (4)
Showing 4 of 4 trials
NCT04975958Phase 1
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
NCT05358691Phase 1
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
NCT05191667Phase 1
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
NCT04432857Phase 1
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4